Background: Nasal polyposis is a multifactorial disease characterized by a chronic eosinophilic inflammation of the sinus mucosa, often associated with asthma and aspirin sensitivity. We have recently shown that the presence of IgE antibodies to Staphylococcus aureus enterotoxins (SAEs) was related to the severity of eosinophilic inflammation in nasal polyp tissue. In this study, we therefore aimed to determine, whether aspirin sensitivity was related to an immune response to SAEs, and how both criteria would be related to eosinophilic inflammation. Methods: 40 subjects with nasal polyposis (NP) were classified as aspirin-sensitive (n = 13, ASNP) or aspirin-tolerant (n = 27, ATNP) based on a bronchial aspirin challenge test. Homogenates prepared from nasal polyp tissue and inferior nasal turbinates from healthy subjects (n = 12) were analyzed for concentrations of IL-5 by enzyme immunoassay and for ECP, total and IgE to a mix of SAEs (A, C, TSST-1) using the ImmunoCAP system. Results: Concentrations of IL-5, ECP, total IgE, and IgE to an SAE mix were significantly increased in ASNP compared with ATNP patients and controls. In addition, a subgroup analysis showed an increase in eosinophilic markers in ATNP-SAE(+) compared to ATNP-SAE(–). This relationship, however, was not found in ATNP-SAE(+) and ATNP-SAE(–) subjects, indicating that SAE immune response is overlapped or not relevant in this condition. Conclusions: Aspirin sensitivity was associated with increased concentrations of eosinophil-related mediators, as well as IgE antibodies to SAEs in nasal polyp tissue. However, a direct impact of S. aureus could not be established. It seems that aspirin sensitivity and immune reactions to SAEs are independently related to eosinophilic inflammation.

Keywords:
Aspirin sensitivity, Nasal polyposis, Staphylococcus aureus enterotoxins, ECP, IgE, Interleukin-5
1.
Pawankar R: Nasal polyposis: An update: Editorial review. Curr Opin Allergy Clin Immunol 2003;3:1–6.
2.
Bachert C, Gevaert P, Holtappels G, van Cauwenberge P: Mediators in nasal polyposis. Curr Allergy Asthma Rep 2002;2:481–487.
3.
Szczeklik A, Nizankowska E, Sanak M, Swierczynska M: Aspirin-induced rhinitis and asthma. Current Opin Allergy Clin Immunol 2001;1:27–33.
4.
Varga EM, Jacobson MR, Masuyama K, Rak S, Till SJ, Darby Y, Hamid Q, Lund V, Scadding GK, Durham SR: Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur Respir J 1999;14:610–615.
5.
Babu KS, Salvi SS: Aspirin and asthma. Chest 2000;118:1470–1476.
6.
Klapan I, Culo F, Culig J, Bukovec Z, Simovic S, Viseslav C, Risavi R, Zeljko B, Sprem N, Miljenko V: Arachidonic acid metabolites and sinonasal polyposis. I. Possible prognostic value. Am J Otolaryngol 1995;16:396–402.
7.
Kowalski ML, Grzegorczyk J, Pawliczak R, Kornatowski T, Wagrowska-Danilewicz M, Danilewicz M: Decreased apoptosis and distinct profile of infiltrating cells in nasal polyps with ASA hypersensitivity. Allergy 2002;57:493–500.
8.
Szczeklik A, Nizankowska E, Duplaga M: Natural history of aspirin-induced asthma. Eur Respir J 2000;16:432–436.
9.
Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A: Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-tolerant asthma. Am J Resp Cell Mol Biol 2000;23:290–296.
10.
Picado C: Aspirin intolerance and nasal polyposis. Curr Allergy Asthma Rep 2002;2:488–493.
11.
Schlievert PM: Role of superantigens in human disease. J Infect Dis 1993;167:997–1002.
12.
Bunikowski R, Mielke MEA, Skarabis H, Worm M, Anagnostopoulos I, Kolde G, Wahn U, Renz H: Evidence for a disease-promoting effect of Staphylococcus aureus- derived exotoxins in atopic dermatitis. J Allergy Clin Immunol 2000;105:814–819.
13.
Shiomori T, Yoshida S, Miyamoto H, Makishima K: Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis. J Allergy Clin Immunol 2000;105:449–454.
14.
Bachert C, Gevaert P, Van Cauwenberge P: Staphylococcus aureus enterotoxins: A key in airway disease. Allergy 2002;57:480–487.
15.
Stierna PL: Nasal polyps: Relationship to infection and inflammation. Allergy Asthma Proc 1996;17:251–257.
16.
Bachert C, Gevaert P, Holtappels G, Johansson SG, Van Cauwenberge P: Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 2001;107:607–614.
17.
Bachert C,Wagenmann M, Hauser U, Rudack C: IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997;99:837–842.
18.
Bachert C, Gevaert P, Holtappels G, Cuvelier C, Van Cauwenberge P: Nasal polyposis: From cytokines to growth. Am J Rhinol 2000;14:279–290.
19.
Fleischer B: Superantigens. APMIS 1994;102:3–12.
20.
Wedi B, Wieczorek D, Stunkel T, Breuer K, Kapp A: Staphylococcal exotoxins exert proinflammatory effects through inhibition of eosinophil apoptosis, increased surface antigen expression (CD11b, CD45, CD54, and CD69), and enhanced cytokine-activated oxidative burst, thereby triggering allergic inflammatory reactions. J Allergy Clin Immunol 2002;109:477–484.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.